PD-1/PD-L1抑制剂在前列腺癌免疫治疗中的研究进展

Research Progress of PD-1/PD-L1 Inhibitors in Immunotherapy of Prostate Cancer

前列腺癌(Prostate cancer, PCa)是常见的泌尿生殖系统恶性肿瘤之一。目前主要的治疗手段是根治性前列腺切除术(Radical prostatectomy, RP)以及雄激素剥夺疗法(Androgen deprivation therapy, ADT),但两者均有其各自的局限性。近年来基因检测技术也在指导免疫疗法迅速发展。其中细胞程序性死亡受体(PD-1)及细胞程序性死亡配体-1 (PD-L1)已成为重要的免疫检查点,在癌症免疫治疗中具有重要价值,通过阻断肿瘤细胞产生的免疫系统的抑制作用,并恢复免疫系统对肿瘤细胞的有害作用。PD-1/PD-L1抑制剂已在许多肿瘤中显示出临床疗效。而随着PD-1/PD-L1在尿路上皮癌方面的研究进展及深入,其在前列腺癌治疗中的作用机制也逐渐明了,本文就近年来免疫疗法在PCa中治疗最新进展作一综述。

Prostate cancer is one of the common malignancies of the genitourinary system. The current main treatment method is radical prostatectomy and androgen deprivation therapy, but both have their own limitations. In recent years, the technology of gene detection is also developing rapidly to guide immunotherapy. One cell programmed death receptor (PD-1) and programmed cell death ligand-1 (PD-L1) has become an important immune checkpoint with important value in cancer immuno-therapy. They work by blocking the suppressive effect produced by tumors on the immune system and restoring the immune system’s harmful effects on tumor cells. PD-1/PD-L1Inhibitors have shown clinical efficacy in many tumors. With the development of PD-1/PD-L1 in urothelial carcino-ma, the mechanism of PD-1/PD-L1 in the treatment of prostate cancer is becoming clear, this article reviews the recent progress of immunotherapy in the treatment of PCa.